NVAX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

SPRZEDAż 66985 min ago

@ $5.28

Wydano: 13 kov. 2024 @ 20:02

Zwrot: -22.55%

Poprzedni sygnał: kov. 13 - 19:12

Poprzedni sygnał: Kupno

Zwrot: 1.36 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs...

Stats
Dzisiejszy wolumen	3.01M
Średni wolumen	7.13M
Kapitalizacja rynkowa	572.41M
EPS	$0 ( 2024-02-28 )
Następna data zysków	( $-1.040 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.760
ATR14	$0.00800 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Trizzino John	Buy	144 000	Restricted Stock Units
2024-03-01	O'hara Elaine	Buy	120 000	Restricted Stock Units
2024-03-01	Kelly James Patrick	Buy	176 000	Restricted Stock Units
2024-03-01	Dubovsky Filip	Buy	144 000	Restricted Stock Units
2024-03-01	Casey Mark J	Buy	12 000	Restricted Stock Units

INSIDER POWER
62.99
Last 99 transactions
Buy: 1 952 927 \| Sell: 481 828

Wolumen Korelacja

Długi: -0.13 (neutral)

Krótki: -0.71 (moderate negative)

Signal:(49.895) Neutral

Novavax Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novavax Inc Korelacja - Waluta/Towar

0.00
( neutral )

0.35
( neutral )

0.00
( neutral )

-0.05
( neutral )

Novavax Inc Finanse

Annual	2023
Przychody:	$983.71M
Zysk brutto:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2023
Przychody:	$983.71M
Zysk brutto:	$704.24M (71.59 %)
EPS:	$-5.41

FY	2022
Przychody:	$1.60B
Zysk brutto:	$696.31M (43.55 %)
EPS:	$-8.42

FY	2021
Przychody:	$1.15B
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-23.44

Financial Reports:

No articles found.

Novavax Inc

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.